1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author @BraunMDPhD @YaleCancer and #PatrickOtt #DerinKeskin #CatherineWu @DanaFarber nature.com/articles/s41586-0… @DanaFarber_GU @OncoAlert @DFCI_NeoVax

Today is a very special day for patients with RCC : CHMP as approved BELZUTIFAN both for VHL disease associated RCC and for advanced renal cell carcinomas (following CPI and 2 VEGFR TKIs) Data presented at @myESMO and published in @NEJM

We just published a review of lessons farmers have learned for how to control pesticide resistance from evolving, and how to apply those to oncology to prevent cancers from evolving therapeutic resistance: bit.ly/48OfFdX

Our Chair, Dr Michael Jewett, was pleased to participate in the International Neoadjuvant Renal Cancer Consortium Meeting in Amsterdam on October 24-25. The IKCC was pleased to support expert clinicians and scientists committed to addressing an unmet need in the treatment of kidney cancer patients. It was a great opportunity to continue discussions from a meeting in January with experts representing urologists, medical oncologists, radiologists, pathologists and clinician scientists, as well representatives from patient organisations. #KidneyCancer

1/23 We are excited to announce that our most recent study “In vivo dendritic cell reprogramming for cancer immunotherapy” was published in @ScienceMagazine. science.org/doi/10.1126/scie… Here is a summary of what we discovered!

Delighted 🤩 to see our work on how Vit D regulate gut microbiome 🦠 to facilitate cancer immunity finally out in @ScienceMagazine! Kudos to the formidable @giampazolias, Team @ReiseSousaLab & all collaborators for getting it to the finish line! Curious to hear what you think👇